News
Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.
Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...
Eli Lilly & Co’s experimental obesity pill orforglipron helped patients lose 9.6% of their body weight in a late-stage trial, ...
In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior ...
Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.
3hon MSN
Cramer's Stop Trading: Eli Lilly
Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly. Fed Governor Lisa Cook Responds After Trump Fires Her ...
While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...
Eli Lilly and Co. (NYSE:LLY) is currently the best performer in the S&P 500 (SP500), after the pharmaceutical announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback